The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gogolev A.B.

Petrov National Medical Research Center of Oncology

Urezkova M.M.

Petrov National Medical Research Center of Oncology

Kudaibergenova A.G.

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia

Changes in the WHO classification (2020) of soft tissue tumors

Authors:

Gogolev A.B., Urezkova M.M., Kudaibergenova A.G.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2023;85(1): 43‑50

DOI: 10.17116/patol20238501143

Views: 2109

Downloaded: 157

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Gogolev AB, Urezkova MM, Kudaibergenova AG. Changes in the WHO classification (2020) of soft tissue tumors. Russian Journal of Archive of Pathology. 2023;85(1):43‑50. (In Russ.)
https://doi.org/10.17116/patol20238501143

Подписка 2025 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata

The article provides an overview of the main changes in the current (2020) WHO classification of soft tissue tumors, as well as selected updates that have occurred since the release of the classification.

Keywords:

soft tissue tumors
WHO classification

Authors:

Gogolev A.B.

Petrov National Medical Research Center of Oncology

Urezkova M.M.

Petrov National Medical Research Center of Oncology

Kudaibergenova A.G.

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia

Received:

06.10.2022

Accepted:

26.10.2022

List of references:

  1. Creytens D, Mariño-Enriquez A. Atypical spindle cell/pleomorphic lipomatous tumour. In: WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020.
  2. Mariño-Enriquez A, Nascimento AF, Ligon AH, Liang C, Fletcher CD. Atypical spindle cell lipomatous tumor: clinicopathologic characterization of 232 cases demonstrating a morphologic spectrum. Am J Surg Pathol. 2017;41(2):234-244.  https://doi.org/10.1097/PAS.0000000000000770
  3. Creytens D, Mentzel T, Ferdinande L, Lecoutere E, van Gorp J, Atanesyan L, de Groot K, Savola S, Van Roy N, Van Dorpe J, et al. «Atypical» pleomorphic lipomatous tumor: a clinicopathologic, immunohistochemical and molecular study of 21 cases, emphasizing its relationship to atypical spindle cell lipomatous tumor and suggesting a morphologic spectrum (atypical spindle cell/pleomorphic lipomatous tumor). Am J Surg Pathol. 2017;41(11):1443-1455. https://doi.org/10.1097/PAS.0000000000000936
  4. Mentzel T, Palmedo G, Kuhnen C. Well-differentiated spindle cell liposarcoma («atypical spindle cell lipomatous tumor») does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. Mod Pathol. 2010;23(5):729-736.  https://doi.org/10.1038/modpathol.2010.66
  5. Boland JM, Colby TV, Folpe AL. Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features. Am J Surg Pathol. 2012;36(9):1395-1403. https://doi.org/10.1097/PAS.0b013e3182562bc1
  6. Creytens D, van Gorp J, Ferdinande L, Van Roy N, Libbrecht L. Array-based comparative genomic hybridization analysis of a pleomorphic myxoid liposarcoma. J Clin Pathol. 2014;67(9):834-835.  https://doi.org/10.1136/jclinpath-2014-202420
  7. Hofvander J, Jo VY, Ghanei I, Gisselsson D, Mårtensson E, Mertens F. Comprehensive genetic analysis of a paediatric pleomorphic myxoid liposarcoma reveals near-haploidization and loss of the RB1 gene. Histopathology. 2016;69(1):141-147.  https://doi.org/10.1111/his.12913
  8. Demicco EG, Fritchie KJ, Han A. Solitary fibrous tumour. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft Tissue and Bone Tumours. 5th ed. World Health Organization; 2020: 104-108. 
  9. Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE, Lazar AJ, Wang WL. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol. 2012;25(9):1298-1306. https://doi.org/10.1038/modpathol.2012.83
  10. Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ, Wang WL. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathol. 2017;30(10):1433-1442. https://doi.org/10.1038/modpathol.2017.54
  11. Rekhi B, Folpe AL, Yu L. Superficial CD34-positive fibroblastic tumour. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;114-115. 
  12. Carter JM, Weiss SW, Linos K, DiCaudo DJ, Folpe AL. Superficial CD34-positive fibroblastic tumor: report of 18 cases of a distinctive low-grade mesenchymal neoplasm of intermediate (borderline) malignancy. Mod Pathol. 2014;27(2):294-302.  https://doi.org/10.1038/modpathol.2013.139
  13. Lao IW, Yu L, Wang J. Superficial CD34-positive fibroblastic tumour: a clinicopathological and immunohistochemical study of an additional series. Histopathology. 2017;70(3):394-401.  https://doi.org/10.1111/his.13088
  14. Montgomery EA, Umetsu SE. Anastomosing haemangioma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;150-151. 
  15. North PE. Tufted angioma and kaposiform haemangioendothelioma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;190-192. 
  16. Bovée JVMG, Wang J, Huang SC. Epithelioid haemangioma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;152-153. 
  17. Huang SC, Zhang L, Sung YS, Chen CL, Krausz T, Dickson BC, Kao YC, Agaram NP, Fletcher CD, Antonescu CR. Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol. 2015;39(10):1313-1321. https://doi.org/10.1097/PAS.0000000000000469
  18. Watanabe R, Schafernak KT, Soares FA. EBV-associated smooth muscle tumour. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;190-192. 
  19. Deyrup AT, Lee VK, Hill CE, Cheuk W, Toh HC, Kesavan S, Chan EW, Weiss SW. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol. 2006;30(1):75-82.  https://doi.org/10.1097/01.pas.0000178088.69394.7b
  20. Hussein K, Rath B, Ludewig B, Kreipe H, Jonigk D. Clinico-pathological characteristics of different types of immunodeficiency-associated smooth muscle tumours. Eur J Cancer. 2014;50(14):2417-2424. https://doi.org/10.1016/j.ejca.2014.06.006
  21. Magg T, Schober T, Walz C, Ley-Zaporozhan J, Facchetti F, Klein C, Hauck F. Epstein-Barr virus+ smooth muscle tumors as manifestation of primary immunodeficiency disorders. Front Immunol. 2018;9:368.  https://doi.org/10.3389/fimmu.2018.00368
  22. Purgina B, Rao UN, Miettinen M, Pantanowitz L. AIDS-related EBV-associated smooth muscle tumors: a review of 64 published cases. Patholog Res Int. 2011;2011:561548. https://doi.org/10.4061/2011/561548
  23. Fletcher CDM, Mertens F. Inflammatory leiomyosarcoma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;193-194. 
  24. Merchant W, Calonje E, Fletcher CD. Inflammatory leiomyosarcoma: a morphological subgroup within the heterogeneous family of so-called inflammatory malignant fibrous histiocytoma. Histopathology. 1995;27(6):525-532.  https://doi.org/10.1111/j.1365-2559.1995.tb00323.x
  25. Arbajian E, Köster J, Vult von Steyern F, Mertens F. Inflammatory leiomyosarcoma is a distinct tumor characterized by nearhaploidization, few somatic mutations, and a primitive myogenic gene expression signature. Mod Pathol. 2018;31(1):93-100.  https://doi.org/10.1038/modpathol.2017.113
  26. Agaram NP, Szuhai K. Spindle cell/sclerosing rhabdomyosarcoma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;211-213. 
  27. Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, Zin A, Agaram NP, LaQuaglia MP, Wexler LH, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40(2):224-235.  https://doi.org/10.1097/PAS.0000000000000538
  28. Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: an update. Virchows Arch. 2020;476(1):97-108.  https://doi.org/10.1007/s00428-019-02676-9
  29. Rekhi B, Upadhyay P, Ramteke MP, Dutt A. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes. Mod Pathol. 2016;29(12):1532-1540. https://doi.org/10.1038/modpathol.2016.144
  30. Huang SC, Antonescu CR. Ectomesenchymoma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;214-215. 
  31. Huang SC, Alaggio R, Sung YS, Chen CL, Zhang L, Kao YC, Agaram NP, Wexler LH, Antonescu CR. Frequent HRAS mutations in malignant ectomesenchymoma: overlapping genetic abnormalities with embryonal rhabdomyosarcoma. Am J Surg Pathol. 2016;40(7):876-885.  https://doi.org/10.1097/PAS.0000000000000612
  32. Antonescu CR, Stratakis CA, Woodruff JM. Melanotic schwannoma. In: Fletcher CD, Bridge JA, Hogendoorn CW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. World Health Organization; 2013;173. 
  33. Perry A, Reuss DE, Rodriguez F. Neurofibroma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;232-236. 
  34. Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1 — a consensus overview. Hum Pathol. 2017;67:1-10.  https://doi.org/10.1016/j.humpath.2017.05.010
  35. de Álava E, Lessnick SL, Stamenkovic I. Ewing sarcoma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;323-325. 
  36. Sbaraglia M, Righi A, Gambarotti M, Dei Tos AP. Ewing sarcoma and Ewing-like tumors. Virchows Arch. 2020;476(1):109-119.  https://doi.org/10.1007/s00428-019-02720-8
  37. Le Loarer F, Szuhai K, Tirode F. Round cell sarcoma with EWSR1-non-ETS fusions. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours, 5th ed. World Health Organization; 2020;326-329. 
  38. Sadri N, Barroeta J, Pack SD, Abdullaev Z, Chatterjee B, Puthiyaveettil R, Brooks JS, Barr FG, Zhang PJ. Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion. Virchows Arch. 2014;465(2):233-239.  https://doi.org/10.1007/s00428-014-1613-7
  39. Chougule A, Taylor MS, Nardi V, Chebib I, Cote GM, Choy E, Nielsen GP, Deshpande V. Spindle and round cell sarcoma with EWSR1-PATZ1 gene fusion: a sarcoma with polyphenotypic differentiation. Am J Surg Pathol. 2019;43(2):220-228.  https://doi.org/10.1097/PAS.0000000000001183
  40. Antonescu CR, Yoshida A. CIC-rearranged sarcoma. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;330-332. 
  41. Antonescu CR, Owosho AA, Zhang L, Chen S, Deniz K, Huryn JM, Kao YC, Huang SC, Singer S, Tap W, et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41(7):941-949.  https://doi.org/10.1097/PAS.0000000000000846
  42. Yoshida A, Goto K, Kodaira M, Kobayashi E, Kawamoto H, Mori T, Yoshimoto S, Endo O, Kodama N, Kushima R, et al. CIC-rearranged sarcomas: a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol. 2016;40(3):313-323.  https://doi.org/10.1097/PAS.0000000000000570
  43. Gambarotti M, Benini S, Gamberi G, Cocchi S, Palmerini E, Sbaraglia M, Donati D, Picci P, Vanel D, Ferrari S, et al. CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone: a single-institution morphological and molecular analysis of seven cases. Histopathology. 2016;69(4):624-634.  https://doi.org/10.1111/his.12985
  44. Hung YP, Fletcher CD, Hornick JL. Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. Mod Pathol. 2016;29(11):1324-1334. https://doi.org/10.1038/modpathol.2016.140
  45. Antonescu CR, Puls F, Tirode F. Sarcoma with BCOR genetic alterations. In: The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Soft tissue and bone tumours. 5th ed. World Health Organization; 2020;333-335. 
  46. Pierron G, Tirode F, Lucchesi C, Reynaud S, Ballet S, Cohen-Gogo S, Perrin V, Coindre JM, Delattre O. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet. 2012; 44(4):461-466.  https://doi.org/10.1038/ng.1107
  47. Martinez AP, Fritchie KJ, Weiss SW, Agaimy A, Haller F, Huang HY, Lee S, Bahrami A, Folpe AL. Histiocyte-rich rhabdomyoblastic tumor: rhabdomyosarcoma, rhabdomyoma, or rhabdomyoblastic tumor of uncertain malignant potential? A histologically distinctive rhabdomyoblastic tumor in search of a place in the classification of skeletal muscle neoplasms. Mod Pathol. 2019;32(3):446-457.  https://doi.org/10.1038/s41379-018-0145-0
  48. Michal M, Rubin BP, Kazakov DV, Michalová K, Šteiner P, Grossmann P, Hájková V, Martínek P, Švajdler M, Agaimy A, et al. Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor. Virchows Arch. 2020;477(2):219-230.  https://doi.org/10.1007/s00428-020-02774-z
  49. Cloutier JM, Charville GW, Mertens F, Sukov W, Fritchie K, Perry KD, Edgar M, Rowsey RA, Folpe AL. «Inflammatory Leiomyosarcoma» and «Histiocyte-Rich Rhabdomyoblastic Tumor»: a clinicopathological, immunohistochemical and genetic study of 13 cases, with a proposal for reclassification as «Inflammatory Rhabdomyoblastic Tumor». Mod Pathol. 2021;34(4):758-769.  https://doi.org/10.1038/s41379-020-00703-8
  50. Geiersbach K, Kleven DT, Blankenship HT, Fritchie K, Folpe AL. Inflammatory rhabdomyoblastic tumor with progression to high-grade rhabdomyosarcoma. Mod Pathol. 2021;34(5):1035-1036. https://doi.org/10.1038/s41379-021-00791-0
  51. Folpe AL, Morris RJ, Weiss SW. Soft tissue giant cell tumor of low malignant potential: a proposal for the reclassification of malignant giant cell tumor of soft parts. Mod Pathol. 1999;12(9):894-902. 
  52. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45(12):1479-1482. https://doi.org/10.1038/ng.2814
  53. Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, Jundt G, Hamoudi R, Wedge DC, Loo PV, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1(2):113-123.  https://doi.org/10.1002/cjp2.13
  54. Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, Gibbons R, Tirabosco R, O’Donnell P, Flanagan AM. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41(8):1059-1068. https://doi.org/10.1097/PAS.0000000000000859
  55. Lee JC, Liang CW, Fletcher CD. Giant cell tumor of soft tissue is genetically distinct from its bone counterpart. Mod Pathol. 2017;30(5):728-733.  https://doi.org/10.1038/modpathol.2016.236
  56. Mancini I, Righi A, Gambarotti M, Picci P, Dei Tos AP, Billings SD, Simi L, Franchi A. Phenotypic and molecular differences between giant-cell tumour of soft tissue and its bone counterpart. Histopathology. 2017;71(3):453-460.  https://doi.org/10.1111/his.13249
  57. Agaimy A, Michal M, Stoehr R, Ferrazzi F, Fabian P, Michal M, Franchi A, Haller F, Folpe AL, Kösemehmetoğlu K. Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors. Mod Pathol. 2021;34(8):1507-1520. https://doi.org/10.1038/s41379-021-00789-8
  58. Fritchie KJ, Torres-Mora J, Inwards C, Thway K, Vaiyapuri S, Jackson R, Minn K, Halling K, Arndt C, Houdek MT, et al. Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Mod Pathol. 2020;33(10):1889-1895. https://doi.org/10.1038/s41379-020-0562-8

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.